Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879720 | 0.74 | ESR1 (0.35) | ESR1ESR2 | |
| SCHEMBL6882948 | 0.72 | TSHR (0.38) | METAP2METAP1ESR1ESR2ALDH1A1 | |
| Bromide SCHEMBL6876839 | 0.71 | TSHR (0.37) | METAP2METAP1ESR1ESR2ALDH1A1 | |
| SCHEMBL11956156 | 0.69 | ESR1 (0.49) | ESR1ESR2ALDH1A1HPGD | |
| SCHEMBL28838045 | 0.60 | — | — | |
| SCHEMBL807517 | 0.60 | — | — | |
| SCHEMBL1924446 | 0.58 | — | — | |
| SCHEMBL1532884 | 0.57 | ESR1 (0.50) | ESR1ESR2 | |
| SCHEMBL8193278 | 0.57 | ESR1 (0.50) | ESR1ESR2ALDH1A1 | |
| SCHEMBL23963097 | 0.57 | ESR1 (0.46) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-12 | — | — | US | disclosed |
| EP-1395592-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA Pharma AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094831-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | PGLS, PLPBP, PDXK | METAP2 759/4885METAP1 680/4885ESR1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.